Tissue Genesis, founded in 2001 and based in Honolulu, United States, is a pioneer in advanced tissue engineering and cell therapy solutions. The company’s core mission is to address medical needs, particularly peripheral vascular disease, by utilizing a patient’s own cells to engineer superior grafts. Their flagship product, the Icellator® 2 system, is an automated point-of-care device that extracts adult stem cells from adipose tissue, providing Stromal Vascular Fraction (SVF) cell yields in just 65 minutes. This innovative technology is currently approved for use in The Bahamas and is undergoing FDA-approved IDE studies in the USA.

Notable figures affiliated with Tissue Genesis include experts in bio-engineering and cell culture modeling who have developed advanced cell biology flight hardware for NASA, NIH, and DOD on the Space Shuttle and ISS. The company has achieved significant milestones, including the approval of their Icellator® 2 system for clinical use in The Bahamas and ongoing FDA studies in the USA. Tissue Genesis has made a substantial impact on the field of regenerative medicine, offering promising solutions for vascular disease and other medical conditions through their cutting-edge cell processing technology.